$ATRS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ANTARES PHARMA, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ANTARES PHARMA, INC.. Get notifications about new insider transactions in ANTARES PHARMA, INC. for free.
Page: < prev 1 2 3 4 5 6 ... 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Tursi James Patrick | EVP, Chief Medical ... | Option Exercise | A | 2.92 | 90,788 | 265,101 | 90,788 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Tursi James Patrick | EVP, Chief Medical ... | Grant | A | 2.92 | 45,205 | 131,999 | 45,205 | 0 to 45.2 K |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Option Exercise | A | 2.92 | 170,227 | 497,063 | 170,227 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 2.92 | 84,760 | 247,499 | 386,261 | 301.5 K to 386.3 K (+28.11 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Option Exercise | A | 2.92 | 181,575 | 530,199 | 181,575 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Grant | A | 2.92 | 90,411 | 264,000 | 485,610 | 395.2 K to 485.6 K (+22.88 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | A | 2.92 | 567,423 | 1,656,875 | 567,423 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Grant | A | 2.92 | 282,534 | 824,999 | 1,849,336 | 1.6 M to 1.8 M (+18.03 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.81 | 11,678 | 32,815 | 301,501 | 313.2 K to 301.5 K (-3.73 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.81 | 11,678 | 32,815 | 301,501 | 313.2 K to 301.5 K (-3.73 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.81 | 12,922 | 36,311 | 313,179 | 326.1 K to 313.2 K (-3.96 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.81 | 12,922 | 36,311 | 313,179 | 326.1 K to 313.2 K (-3.96 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Payment of Exercise | F | 2.81 | 8,684 | 24,402 | 395,199 | 403.9 K to 395.2 K (-2.15 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Payment of Exercise | F | 2.81 | 9,609 | 27,001 | 403,883 | 413.5 K to 403.9 K (-2.32 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.81 | 44,225 | 124,272 | 1,566,802 | 1.6 M to 1.6 M (-2.75 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.81 | 48,936 | 137,510 | 1,611,027 | 1.7 M to 1.6 M (-2.95 %) |
| Jun 04 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.79 | 52,559 | 146,640 | 1,659,963 | 1.7 M to 1.7 M (-3.07 %) |
| Jun 04 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.79 | 15,421 | 43,025 | 326,101 | 341.5 K to 326.1 K (-4.52 %) |
| May 03 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 0.53 | 30,000 | 15,900 | 0 | |
| May 03 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 2.67 | 30,000 | 79,968 | 160,213 | 190.2 K to 160.2 K (-15.77 %) |
| May 03 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 0.53 | 30,000 | 15,900 | 190,213 | 160.2 K to 190.2 K (+18.73 %) |
| Apr 10 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 0.53 | 30,000 | 15,900 | 0 | |
| Apr 10 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 0.53 | 62,078 | 32,901 | 0 | |
| Apr 10 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 3.00 | 92,078 | 276,243 | 239,892 | 332 K to 239.9 K (-27.74 %) |
| Apr 10 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 0.53 | 30,000 | 15,900 | 331,970 | 302 K to 332 K (+9.93 %) |
| Apr 10 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 0.53 | 62,078 | 32,901 | 301,970 | 239.9 K to 302 K (+25.88 %) |
| Feb 28 2019 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 3.65 | 200,000 | 730,000 | 9,385,848 | 9.6 M to 9.4 M (-2.09 %) |
| Feb 22 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 3.20 | 32,386 | 103,635 | 341,522 | 373.9 K to 341.5 K (-8.66 %) |
| Feb 22 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 0.00 | 84,735 | 0 | 373,908 | 289.2 K to 373.9 K (+29.30 %) |
| Feb 22 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 3.20 | 72,245 | 231,184 | 1,712,522 | 1.8 M to 1.7 M (-4.05 %) |
| Feb 22 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Grant | A | 0.00 | 254,205 | 0 | 1,784,767 | 1.5 M to 1.8 M (+16.61 %) |
| Dec 14 2018 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Option Exercise | A | 3.11 | 20,000 | 62,200 | 20,000 | |
| Oct 04 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 3.79 | 400,000 | 1,516,000 | 9,585,848 | 10 M to 9.6 M (-4.01 %) |
| Aug 23 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 0.47 | 43,000 | 20,210 | 0 | |
| Aug 23 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 3.75 | 43,000 | 161,250 | 1,530,562 | 1.6 M to 1.5 M (-2.73 %) |
| Aug 23 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 0.47 | 43,000 | 20,210 | 1,573,562 | 1.5 M to 1.6 M (+2.81 %) |
| Aug 15 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 3.09 | 49,507 | 152,977 | 9,985,848 | 10 M to 10 M (-0.49 %) |
| Aug 10 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 3.09 | 250,493 | 774,023 | 10,035,355 | 10.3 M to 10 M (-2.44 %) |
| Aug 07 2018 | ATRS | ANTARES PHARMA, IN ... | Tursi James Patrick | EVP, Chief Medical ... | Option Exercise | A | 2.89 | 150,000 | 433,500 | 150,000 | |
| Jun 20 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.95 | 565 | 1,667 | 10,285,848 | 10.3 M to 10.3 M (-0.01 %) |
| Jun 13 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.77 | 100,000 | 277,000 | 10,286,413 | 10.4 M to 10.3 M (-0.96 %) |
| Jun 13 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.69 | 100,000 | 269,000 | 10,386,413 | 10.5 M to 10.4 M (-0.95 %) |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | A | 2.70 | 76,548 | 206,680 | 76,548 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Option Exercise | A | 2.70 | 76,548 | 206,680 | 76,548 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | A | 2.70 | 153,097 | 413,362 | 153,097 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | A | 2.70 | 76,548 | 206,680 | 76,548 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | A | 2.70 | 76,548 | 206,680 | 76,548 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | A | 2.70 | 76,548 | 206,680 | 76,548 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Option Exercise | A | 2.70 | 177,453 | 479,123 | 177,453 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 2.70 | 91,667 | 247,501 | 289,173 | 197.5 K to 289.2 K (+46.41 %) |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.70 | 12,923 | 34,892 | 197,506 | 210.4 K to 197.5 K (-6.14 %) |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Option Exercise | A | 2.70 | 177,453 | 479,123 | 177,453 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Grant | A | 2.70 | 91,667 | 247,501 | 413,492 | 321.8 K to 413.5 K (+28.48 %) |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Payment of Exercise | F | 2.70 | 9,609 | 25,944 | 321,825 | 331.4 K to 321.8 K (-2.90 %) |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | A | 2.70 | 591,510 | 1,597,077 | 591,510 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Grant | A | 2.70 | 305,556 | 825,001 | 1,530,562 | 1.2 M to 1.5 M (+24.94 %) |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.70 | 32,031 | 86,484 | 1,225,006 | 1.3 M to 1.2 M (-2.55 %) |
| Jun 07 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.70 | 20,259 | 54,699 | 10,486,413 | 10.5 M to 10.5 M (-0.19 %) |
| Jun 07 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.70 | 23,129 | 62,448 | 10,506,672 | 10.5 M to 10.5 M (-0.22 %) |
| Jun 05 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.55 | 100,000 | 255,000 | 10,529,801 | 10.6 M to 10.5 M (-0.94 %) |
| Jun 05 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.65 | 100,000 | 265,000 | 10,629,801 | 10.7 M to 10.6 M (-0.93 %) |
| Jun 05 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.70 | 56,612 | 152,852 | 10,729,801 | 10.8 M to 10.7 M (-0.52 %) |
| Jun 05 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.69 | 34,402 | 92,541 | 1,257,037 | 1.3 M to 1.3 M (-2.66 %) |
| Jun 05 2018 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.69 | 15,422 | 41,485 | 210,429 | 225.9 K to 210.4 K (-6.83 %) |
| Jun 01 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.60 | 78,938 | 205,239 | 10,786,413 | 10.9 M to 10.8 M (-0.73 %) |
| Jun 01 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.55 | 100,000 | 255,000 | 10,865,351 | 11 M to 10.9 M (-0.91 %) |
| May 30 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.43 | 13,480 | 32,756 | 1,291,439 | 1.3 M to 1.3 M (-1.03 %) |
| May 24 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.50 | 100,000 | 250,000 | 10,965,351 | 11.1 M to 11 M (-0.90 %) |
| May 24 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.53 | 94,682 | 239,545 | 11,065,351 | 11.2 M to 11.1 M (-0.85 %) |
| May 24 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.53 | 5,318 | 13,455 | 11,160,033 | 11.2 M to 11.2 M (-0.05 %) |
| May 22 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.60 | 21,062 | 54,761 | 11,165,351 | 11.2 M to 11.2 M (-0.19 %) |
| May 18 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.55 | 100,000 | 255,000 | 11,186,413 | 11.3 M to 11.2 M (-0.89 %) |
| May 18 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.52 | 100,000 | 252,000 | 11,286,413 | 11.4 M to 11.3 M (-0.88 %) |
| May 16 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.50 | 100,000 | 250,000 | 11,386,413 | 11.5 M to 11.4 M (-0.87 %) |
| May 16 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.50 | 100,000 | 250,000 | 11,486,413 | 11.6 M to 11.5 M (-0.86 %) |
| May 14 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 0.85 | 82,500 | 70,125 | 0 | |
| May 14 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.52 | 30,052 | 75,731 | 1,304,919 | 1.3 M to 1.3 M (-2.25 %) |
| May 14 2018 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 0.85 | 82,500 | 70,125 | 1,334,971 | 1.3 M to 1.3 M (+6.59 %) |
| May 14 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.47 | 100,000 | 247,000 | 11,586,413 | 11.7 M to 11.6 M (-0.86 %) |
| May 14 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.36 | 100,000 | 236,000 | 11,686,413 | 11.8 M to 11.7 M (-0.85 %) |
| May 11 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.47 | 150,000 | 371,190 | 11,786,413 | 11.9 M to 11.8 M (-1.26 %) |
| May 11 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Sell | S | 2.46 | 150,000 | 369,210 | 11,936,413 | 12.1 M to 11.9 M (-1.24 %) |
| May 07 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 0.85 | 30,000 | 25,500 | 0 | |
| May 07 2018 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 0.85 | 30,000 | 25,500 | 12,086,413 | 12.1 M to 12.1 M (+0.25 %) |
| Apr 02 2018 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 0.85 | 32,407 | 27,546 | 0 | |
| Apr 02 2018 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 0.85 | 32,407 | 27,546 | 239,892 | 207.5 K to 239.9 K (+15.62 %) |
| Oct 11 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 0.50 | 188,600 | 94,300 | 0 | |
| Oct 11 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 0.85 | 30,000 | 25,500 | 0 | |
| Oct 11 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 4.05 | 200,000 | 810,420 | 207,485 | 407.5 K to 207.5 K (-49.08 %) |
| Oct 11 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 0.50 | 188,600 | 94,300 | 407,485 | 218.9 K to 407.5 K (+86.16 %) |
| Oct 11 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 4.05 | 30,000 | 121,500 | 218,885 | 248.9 K to 218.9 K (-12.05 %) |
| Oct 11 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 0.85 | 30,000 | 25,500 | 248,885 | 218.9 K to 248.9 K (+13.71 %) |
| Oct 05 2017 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 0.85 | 30,000 | 25,500 | 0 | |
| Oct 05 2017 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 3.50 | 30,000 | 105,000 | 160,213 | 190.2 K to 160.2 K (-15.77 %) |
| Oct 05 2017 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 0.85 | 30,000 | 25,500 | 190,213 | 160.2 K to 190.2 K (+18.73 %) |
| Jun 13 2017 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Senior Vice Preside ... | Buy | P | 2.79 | 130,000 | 363,272 | 331,434 | 201.4 K to 331.4 K (+64.54 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Senior Vice Preside ... | Option Exercise | A | 2.66 | 217,725 | 579,149 | 217,725 | |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Senior Vice Preside ... | Grant | A | 2.66 | 101,434 | 269,814 | 201,434 | 100 K to 201.4 K (+101.43 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Option Exercise | A | 2.66 | 217,725 | 579,149 | 217,725 | |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Grant | A | 2.66 | 101,434 | 269,814 | 225,851 | 124.4 K to 225.9 K (+81.53 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Payment of Exercise | F | 2.57 | 16,633 | 42,747 | 124,417 | 141.1 K to 124.4 K (-11.79 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | A | 2.66 | 725,751 | 1,930,498 | 725,751 | |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Grant | A | 2.66 | 338,115 | 899,386 | 1,175,637 | 1.5 M to 1.2 M (-22.34 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.57 | 38,034 | 97,747 | 837,522 | 875.6 K to 837.5 K (-4.34 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.51 | 3,390 | 8,509 | 875,556 | 878.9 K to 875.6 K (-0.39 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.51 | 14,903 | 37,407 | 878,946 | 893.8 K to 878.9 K (-1.67 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.37 | 1,763 | 4,178 | 893,849 | 895.6 K to 893.8 K (-0.20 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Grant | A | 0.00 | 5,612 | 0 | 895,612 | 890 K to 895.6 K (+0.63 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | A | 2.66 | 80,318 | 213,646 | 80,318 | |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | A | 2.66 | 80,318 | 213,646 | 80,318 | |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | A | 2.66 | 160,636 | 427,292 | 160,636 | |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Option Exercise | A | 2.66 | 80,318 | 213,646 | 80,318 | |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | A | 2.66 | 80,318 | 213,646 | 80,318 | |
| Apr 12 2017 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Gift | G | 2.80 | 50,000 | 140,000 | 52,778 | 102.8 K to 52.8 K (-48.65 %) |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 1.65 | 3,000 | 4,950 | 0 | |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 1.65 | 37,000 | 61,050 | 3,000 | |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 3.00 | 3,000 | 9,000 | 890,002 | 893 K to 890 K (-0.34 %) |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 1.65 | 3,000 | 4,950 | 893,002 | 890 K to 893 K (+0.34 %) |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 3.00 | 37,000 | 111,070 | 890,002 | 927 K to 890 K (-3.99 %) |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 1.65 | 37,000 | 61,050 | 927,002 | 890 K to 927 K (+4.16 %) |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 1.65 | 21,762 | 35,907 | 0 | |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 1.65 | 20,000 | 33,000 | 21,762 | |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 2.90 | 21,762 | 63,112 | 218,885 | 240.6 K to 218.9 K (-9.04 %) |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 1.65 | 21,762 | 35,907 | 240,647 | 218.9 K to 240.6 K (+9.94 %) |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 2.88 | 20,000 | 57,570 | 218,885 | 238.9 K to 218.9 K (-8.37 %) |
| Apr 05 2017 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 1.65 | 20,000 | 33,000 | 238,885 | 218.9 K to 238.9 K (+9.14 %) |
| Apr 04 2017 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | M | 1.65 | 30,000 | 49,500 | 0 | |
| Apr 04 2017 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | M | 1.65 | 30,000 | 49,500 | 12,056,413 | 12 M to 12.1 M (+0.25 %) |
| Apr 04 2017 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 1.65 | 30,000 | 49,500 | 0 | |
| Apr 04 2017 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 2.91 | 30,000 | 87,276 | 160,213 | 190.2 K to 160.2 K (-15.77 %) |
| Apr 04 2017 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 1.65 | 30,000 | 49,500 | 190,213 | 160.2 K to 190.2 K (+18.73 %) |
| Jan 12 2017 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Buy | J | 0.00 | 2,900,000 | 0 | 12,026,413 | 9.1 M to 12 M (+31.78 %) |
| Dec 29 2016 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 1.23 | 60,000 | 73,800 | 0 | |
| Dec 29 2016 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.35 | 39,717 | 93,335 | 890,002 | 929.7 K to 890 K (-4.27 %) |
| Dec 29 2016 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 1.23 | 60,000 | 73,800 | 929,719 | 869.7 K to 929.7 K (+6.90 %) |
| Dec 12 2016 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Senior Vice Preside ... | Buy | P | 2.03 | 100,000 | 202,500 | 100,000 | 0 to 100 K |
| Dec 05 2016 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 1.23 | 20,000 | 24,600 | 0 | |
| Dec 05 2016 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 1.97 | 20,000 | 39,416 | 218,885 | 238.9 K to 218.9 K (-8.37 %) |
| Dec 05 2016 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 1.23 | 20,000 | 24,600 | 238,885 | 218.9 K to 238.9 K (+9.14 %) |
| Nov 02 2016 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Senior Vice Preside ... | Option Exercise | A | 1.76 | 150,000 | 264,000 | 150,000 | |
| Jun 30 2016 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Grant | A | 1.05 | 11,223 | 11,784 | 869,719 | 858.5 K to 869.7 K (+1.31 %) |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | A | 1.12 | 150,000 | 168,000 | 150,000 | |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Option Exercise | A | 1.12 | 150,000 | 168,000 | 150,000 | |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | A | 1.12 | 300,000 | 336,000 | 300,000 | |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | A | 1.12 | 150,000 | 168,000 | 150,000 | |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Option Exercise | A | 1.12 | 257,900 | 288,848 | 257,900 | |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Grant | A | 1.12 | 121,050 | 135,576 | 141,050 | 20 K to 141.1 K (+605.25 %) |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | A | 1.12 | 150,000 | 168,000 | 150,000 | |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | A | 1.12 | 150,000 | 168,000 | 150,000 | |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | Fickenscher James E | Senior Vice Preside ... | Option Exercise | A | 1.12 | 257,900 | 288,848 | 257,900 |